42 related articles for article (PubMed ID: 24523296)
1. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers.
Coyle DT; Woodworth TS; Moeny D; Staffa J; Meyer T; Woods C; Welch EC; Haynes K; Toh S; Maro JC
J Manag Care Spec Pharm; 2020 May; 26(5):668-672. PubMed ID: 32347183
[TBL] [Abstract][Full Text] [Related]
3. Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.
Detert Oude Weme SEH; Hulskotte LMG; Vervenne WL; Imholz ALT; Cremers RGHM; Taxis K; Reyners AKL; van Berlo-van de Laar IRF; Jansman FGA; Benoist GE
Clin Pharmacokinet; 2023 Jul; 62(7):989-996. PubMed ID: 37162620
[TBL] [Abstract][Full Text] [Related]
4. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
5. Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study.
Decaix T; Gautier S; Royer L; Laprévote O; Tritz T; Siguret V; Teillet L; Sellier C; Pépin M
Aging Clin Exp Res; 2023 Nov; 35(11):2471-2481. PubMed ID: 37861957
[TBL] [Abstract][Full Text] [Related]
6. Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward.
Beierle JA; Yao EJ; Goldstein SI; Lynch WB; Scotellaro JL; Shah AA; Sena KD; Wong AL; Linnertz CL; Averin O; Moody DE; Reilly CA; Peltz G; Emili A; Ferris MT; Bryant CD
J Pharmacol Exp Ther; 2022 Aug; 382(2):167-180. PubMed ID: 35688478
[TBL] [Abstract][Full Text] [Related]
7. Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism.
Deodhar M; Turgeon J; Michaud V
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575542
[TBL] [Abstract][Full Text] [Related]
8. Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone.
Pednekar D; Russell J; Bardolia C; Thacker D; Amin NS
Sr Care Pharm; 2024 Apr; 39(4):137-142. PubMed ID: 38528335
[TBL] [Abstract][Full Text] [Related]
9. Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7.
Shum S; Isoherranen N
AAPS J; 2021 Jan; 23(1):24. PubMed ID: 33438174
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.
Korjamo T; Tolonen A; Ranta VP; Turpeinen M; Kokki H
Front Pharmacol; 2011; 2():87. PubMed ID: 22291644
[TBL] [Abstract][Full Text] [Related]
11. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.
Davies SJ; Eayrs S; Pratt P; Lennard MS
Br J Clin Pharmacol; 2004 Apr; 57(4):464-72. PubMed ID: 15025745
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Daily Average Consumption Of Oxycodone Controlled Release (OxyContin CR) And Oxymorphone Extended Release (Opana ER) In Patients With Low Back Pain.
Berner T; Thomson H; Hartry A; Puenpatom RA; Ben-Joseph R; Szeinbach SL
P T; 2011 Mar; 36(3):139-44. PubMed ID: 21572765
[TBL] [Abstract][Full Text] [Related]
13. A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability.
Makihara K; Yamamoto Y; Miyazaki M; Taguchi M; Sato J; Takase H; Uezono Y
J Pain Palliat Care Pharmacother; 2024 Mar; 38(1):3-12. PubMed ID: 38227839
[TBL] [Abstract][Full Text] [Related]
14. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine.
Moy KV; Ma JD; Morello CM; Atayee RS; Best BM
J Opioid Manag; 2014; 10(1):47-56. PubMed ID: 24604569
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.
Marsousi N; Daali Y; Rudaz S; Almond L; Humphries H; Desmeules J; Samer CF
CPT Pharmacometrics Syst Pharmacol; 2014 Dec; 3(12):e152. PubMed ID: 25518025
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
Hao GT; Zhou HY; Gao HZ; Qu HY; Liang YG; Li YY; Dong RH; Zhang LJ; Wang XF; Liu ZY
Pharmacol Rep; 2014 Feb; 66(1):153-8. PubMed ID: 24905321
[TBL] [Abstract][Full Text] [Related]
17. Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.
Coates S; Lazarus P
J Pharmacol Exp Ther; 2023 Nov; 387(2):150-169. PubMed ID: 37679047
[TBL] [Abstract][Full Text] [Related]
18. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Yunusa I; Gagne JJ; Yoshida K; Bykov K
JAMA Netw Open; 2022 Feb; 5(2):e220194. PubMed ID: 35201310
[TBL] [Abstract][Full Text] [Related]
19. Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats.
Kimbrough A; Kononoff J; Simpson S; Kallupi M; Sedighim S; Palomino K; Conlisk D; Momper JD; de Guglielmo G; George O
Psychopharmacology (Berl); 2020 May; 237(5):1545-1555. PubMed ID: 32114633
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
